We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker p-120 Catenin Distinguishes Conventional Urothelial Carcinoma from Variants

By LabMedica International staff writers
Posted on 24 Aug 2021
Print article
Image: Histopathology of (a) Usual-type high-grade urothelial carcinoma and (b) Positive E-cadherin expression in usual-type high-grade urothelial carcinoma. (Photo courtesy of Emory University School of Medicine)
Image: Histopathology of (a) Usual-type high-grade urothelial carcinoma and (b) Positive E-cadherin expression in usual-type high-grade urothelial carcinoma. (Photo courtesy of Emory University School of Medicine)
Plasmacytoid urothelial carcinoma (PC-UC) is an infrequent and clinically aggressive variant of urothelial carcinoma (UC). Initially, PC-UC was identified based on morphology as a potential mimicker of malignant plasma cell and lymphoid neoplasms and is characterized by loss of E-cadherin (E-Cad)–mediated intercellular adhesion.

Sarcomatoid UC, is another rare and aggressive variant of UC that includes carcinomatous and sarcomatous components (i.e., dedifferentiated carcinoma). The latter can be represented by a nondescript high-grade spindle cell proliferation and/or it can demonstrate more lineage-specific change, including, but not limited to, leiomyosarcomatous, rhabdomyosarcomatous, and chondrosarcomatous differentiation.

Pathologists at the Brigham and Women's Hospital (Boston, MA, USA) included in a study included a total of 58 samples from 55 patients, as three cases had areas of both PC-UC and SUC. The final breakdown included 25 conventional invasive UCs, 22 PC-UCs, six SUCs, and five micropapillary UCs. Specimen types included 45 transurethral resections/bladder biopsies, three cystoprostatectomies, one anterior pelvic exenteration, one abdominoperineal resection, two biopsies of tumor from metastatic sites (one pelvic soft tissue nodule and one peritoneal nodule), one nephroureterectomy, one penectomy, and one autopsy case.

The team performed immunohistochemistry with the Envision Plus/horseradish peroxidase system (Dako Agilent, Carpinteria, CA, USA), a polyclonal antibody to p-120 (BD Biosciences, San Jose, CA, USA), and monoclonal antibodies against E-Cad (Dako Agilent,) and B-Cat (BD Biosciences). Following Tris-buffered saline rinses, the tissues were incubated with the Envision Plus or Novolink Polymer Detection system (Leica Biosystems, Buffalo Grove, IL, USA). Eight PC-UC cases had molecular characterization via the OncoPanel assay developed at the institution.

The scientists reported that E-cadherin, B-Cat, and p-120 showed membranous staining in all conventional and micropapillary UCs. In contrast, most PC-UCs were negative for E-Cad (17/22; 77%) with an additional 2/22 cases (9%) showing cytoplasmic with partial membranous staining. p-120 catenin demonstrated cytoplasmic or negative staining in 21/22 cases (95%). Most SUCs showed an absence of E-Cad (5/6; 83%) and cytoplasmic or negative p-120 in 5/6 cases (83%). Staining for B-Cat was also abnormal in a subset of PC-UCs and SUCs. Five PC-UC cases that harbored CDH1 gene variants were p-120 cytoplasmic positive.

The authors concluded that p-120 catenin is a useful adjunct biomarker to E-Cad in the clinically important distinction of PC-UC and SUC from conventional UC. In particular, the combination of cytoplasmic p-120 and loss of E-Cad is strongly supportive of PC-UC and SUC. The study was published on August 21, 2021 in the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Brigham and Women's Hospital
Dako Agilent
BD Biosciences
Leica Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.